Long-Acting InjectableS

LAIs include more than just antiretroviral therapies, such as Cabenuva or Sunlenca, which are used to treat HIV. They also include treatments such as Apretude, an injectable used as PrEP, Egrifta used to reduce visceral abdominal fat because of lipodystrophy, Serostim for wasting, and Trogarzo which is intravenous salvage therapy for those with multi-drug-resistant HIV infections. These therapies are proven effective, and their cost-benefit may be underappreciated, especially given the public health benefits of reduced new transmissions. There are also broader implications for LAIs and corresponding patient perspectives outside of the HIV space.

Obstacles and operational barriers to timely access to new agents, especially injectables, have increased.  These products are vital to the well-being of people living with HIV/AIDS, as well as the prevention of new HIV diagnoses. The barriers that commonly arise hinder equitable access for PLWHA who rely on ADAP-funded services and other insurance products to obtain them on a regular basis. These same barriers often exist for PrEP. LAIs are powerful tools in the fight against HIV, and those utilizing AIDS Drug Assistance Programs (ADAP) deserve the same equity of care and access as those who are fully insured with more robust financial means. Whether it be geographical logistical challenges, treatment education deficiencies, supply chain issues, or even provider bias, ADAP recipients have many injection therapy barriers to overcome.